Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease

NCT05417126 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Stargardt Disease

Interventions

BIOLOGICAL: Gene Therapy-vMCO-010

Sponsor

Nanoscope Therapeutics Inc.